ENTITY
Celltrion Inc

Celltrion Inc (068270 KS)

475
Analysis
Health CareSouth Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Refresh
22 Apr 2016 10:10

How Korea National Pension Fund Is Exerting Pressure on Companies to Raise Dividends

Korea National Pension Fund (KNPF), the third largest pension fund in the world, has been exerting more pressure on Korean companies to raise their...

Logo
214 Views
Share
bearishCelltrion Inc
09 Apr 2016 05:22

U.S. Remsima Expectations Too Optimistic

USFDA approved Celltrion’s Remsima, a biosimilar for JNJ’s Remicade, for use in treating rheumatoid arthritis, ulcerative colitis, Crohn’s, and...

Share
bearishCelltrion Inc
26 Mar 2016 21:33

Serious Questions to Consider

Our initial post on Celltrion focused on the fundamental risk of whether the company could meet the market's high expectations for its first...

Share
29 Feb 2016 14:39

Share Buybacks in Korea - Top 9 Insights

In this report, we highlight 39 companies that have announced share buybacks in the past three months (Dec 2015 - Feb 2016) in Korea. We provide...

Logo
260 Views
Share
16 Feb 2016 00:59

2016 Major IPOs Pipeline in Korea - Part II

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...

Logo
231 Views
Share
x